KALAMAZOO —Armune Bioscience Inc.raised nearly $9.1 million in a capital round to support further commercialization of a blood test to screen for prostate cancer.
Part of a $9.4 million Series A capital raise, the funding in the Kalamazoo-based firm came from 46 investors, according to a regulatory filing this week with the U.S. Securities and Exchange Commission.
Formed in 2008, Armune Bioscience this year intends to begin raising a subsequent $25 million in Series B growth capital after launching its Apifiny diagnostic blood test last April.
Since signing a deal in December with Quebec City-basedAeterna Zenteris Inc.to co-market Apifiny, Armune has secured a number of deals with labs and provider networks to extend the blood test’s deployment across the U.S. and globally. In the latest agreement, announced Jan. 27, Scottsdale, Ariz.-basedFortified Provider Networkwill make the Apifiny test available to the more than 69 million members.